Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumor Growth”

1,580 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,580 results

Large-scale testing (Phase 3)Study completedNCT00917384
What this trial is testing

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Who this might be right for
Gastric CancerAdenocarcinoma
Eli Lilly and Company 355
Very early researchLooking for participantsNCT07558538
What this trial is testing

A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome

Who this might be right for
ARDS (Moderate or Severe)ARDS (Acute Respiratory Distress Syndrome)
Shanghai Zhongshan Hospital 24
Testing effectiveness (Phase 2)Study completedNCT02187991
What this trial is testing

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Who this might be right for
Breast CancerBreast CarcinomaBreast Tumors+1 more
US Oncology Research 169
Not applicableUnknownNCT06317610
What this trial is testing

Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids

Who this might be right for
Ovarian Cancer
Chongqing University Cancer Hospital 100
Testing effectiveness (Phase 2)Study completedNCT01271725
What this trial is testing

LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

Who this might be right for
Breast Neoplasms
Boehringer Ingelheim 74
Testing effectiveness (Phase 2)Study completedNCT00615758
What this trial is testing

Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV

Who this might be right for
Non Small Cell Lung Cancer
Hellenic Oncology Research Group 50
Testing effectiveness (Phase 2)Ended earlyNCT04066790
What this trial is testing

Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Shanghai Jiao Tong University School of Medicine 12
Large-scale testing (Phase 3)Active Not RecruitingNCT06635447
What this trial is testing

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Who this might be right for
Breast Cancer
AstraZeneca 293
Not applicableNot Yet RecruitingNCT07474025
What this trial is testing

Integrating Peritoneal Histological Growth Patterns Into Preoperative Decision-Making for Colorectal Peritoneal Metastses

Who this might be right for
Peritoneal (Metastatic) CancerColorectal CancerColorectal (Colon or Rectal) Cancer+1 more
Jules Bordet Institute 30
Testing effectiveness (Phase 2)Ended earlyNCT04489940
What this trial is testing

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Neoplasms
EMD Serono Research & Development Institute, Inc. 11
Testing effectiveness (Phase 2)Ended earlyNCT03827850
What this trial is testing

FGFR Inhibitor in FGFR Dysregulated Cancer

Who this might be right for
Lung CancerNSCLCPulmonary Neoplasm+2 more
Lung Cancer Group Cologne 22
Testing effectiveness (Phase 2)UnknownNCT03424759
What this trial is testing

Uncommon EGFR AZD9291

Who this might be right for
Non Small Cell Lung Cancer
Samsung Medical Center 37
Early research (Phase 1)Study completedNCT01928459
What this trial is testing

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Solid Tumors
Novartis Pharmaceuticals 62
Testing effectiveness (Phase 2)Study completedNCT00258960
What this trial is testing

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 49
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479
What this trial is testing

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis
Zhejiang Cancer Hospital 45
Early research (Phase 1)Ended earlyNCT03685591
What this trial is testing

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Who this might be right for
Breast NeoplasmsProstate NeoplasmsNeoplasms, Squamous Cell+6 more
Pfizer 49
Early research (Phase 1)Study completedNCT00006368
What this trial is testing

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more
Novartis Pharmaceuticals 60
Large-scale testing (Phase 3)Active Not RecruitingNCT04765059
What this trial is testing

Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 98
Testing effectiveness (Phase 2)Ended earlyNCT00074334
What this trial is testing

TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma

Who this might be right for
Brain and Central Nervous System Tumors
Pediatric Brain Tumor Consortium 3
Early research (Phase 1)Study completedNCT04572295
What this trial is testing

E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Eisai Co., Ltd. 51
Next Page